Vol. 216, No. 8, August 5, 2019. 10.1084/jem.20190490.

JEM regrets that in the original version of this paper, panels E-G were mistakenly omitted from Fig. 4 due to a production error. The corrected and complete Fig. 4 appears on the following page.

Figure 4.

KLRG1 + ILCs and NKp46 + ILCs show multipotent cytokine production and TF profile. (A) Representative histogram of expression of CD25 or RANKL on KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture on OP9-DL1 cells in the presence of IL-2 and IL-7 with or without TSLP and IL-33 or IL-1β and IL-23 for 7 d. (B) Quantification of CD25 or RANKL expression on after culture as in A (n = 3–8). (C) Representative flow cytometric analysis of intracellular IL-5, IL-13, IFN-γ, and IL-17A in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs, after 7 d culture as in A and subsequently stimulated by PMA/ionomycin for 3 h. (D) Quantification of cytokine production by ELISA in culture supernatants from cells stimulated as in A. The concentration is adjusted to 5,000 cells. (E) Quantification of IFN-γ production by ELISA of ILC subsets cultured on OP9-DL1 cells in the presence of IL-2 and IL-7 with IL-1β and IL-23 or IL-1β and IL-12 for 7 d. (F) Representative flow cytometry of the expression of CD117, NKp44, and CD94 on KLRG1+ ILCs, ILC2, and NKp46+ ILCs after culture as in E. Filled histograms represent isotype control. (G) Representative flow cytometric analysis of intracellular expression of EOMES and T-bet in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture as in E. Data in A, C, F, and G are representative of at least three donors from more than three independent experiments. Cytokines used in all experiments are IL-2 (20 U/ml), IL-7, TSLP, IL-33, IL-1β, IL-23, and IL-12 (all 20 ng/ml). **, P < 0.001; ***, P < 0.0001; ****, P < 0.00001 (one-way ANOVA).

Figure 4.

KLRG1 + ILCs and NKp46 + ILCs show multipotent cytokine production and TF profile. (A) Representative histogram of expression of CD25 or RANKL on KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture on OP9-DL1 cells in the presence of IL-2 and IL-7 with or without TSLP and IL-33 or IL-1β and IL-23 for 7 d. (B) Quantification of CD25 or RANKL expression on after culture as in A (n = 3–8). (C) Representative flow cytometric analysis of intracellular IL-5, IL-13, IFN-γ, and IL-17A in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs, after 7 d culture as in A and subsequently stimulated by PMA/ionomycin for 3 h. (D) Quantification of cytokine production by ELISA in culture supernatants from cells stimulated as in A. The concentration is adjusted to 5,000 cells. (E) Quantification of IFN-γ production by ELISA of ILC subsets cultured on OP9-DL1 cells in the presence of IL-2 and IL-7 with IL-1β and IL-23 or IL-1β and IL-12 for 7 d. (F) Representative flow cytometry of the expression of CD117, NKp44, and CD94 on KLRG1+ ILCs, ILC2, and NKp46+ ILCs after culture as in E. Filled histograms represent isotype control. (G) Representative flow cytometric analysis of intracellular expression of EOMES and T-bet in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture as in E. Data in A, C, F, and G are representative of at least three donors from more than three independent experiments. Cytokines used in all experiments are IL-2 (20 U/ml), IL-7, TSLP, IL-33, IL-1β, IL-23, and IL-12 (all 20 ng/ml). **, P < 0.001; ***, P < 0.0001; ****, P < 0.00001 (one-way ANOVA).

The online and print versions of this article have been corrected. The error appears only in PDF versions downloaded on or before July 31, 2019.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).